Vincent Lawton

The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium.

The International Federation of Pharmaceutical Manufacturers and Traders is a global organization that promotes technology transfer in the pharmaceutical industry. The non-profit company is based in Geneva, Switzerland. The Swiss company believes that technology transfer helps bridge research and development gaps, increases the availability of vaccines and medicines, and stimulates investment in key industrial areas. David Reddy has been the CEO of the company since 2024.

UK Biobank Ltd. is a biomedical database and research resource that contains genetic, lifestyle, and health information from half a million participants aged between 40-69 years in 2006-2010 from across the UK. The organization has over 220 dedicated members of staff, based in multiple locations across the UK. UK Biobank's research resource is a major contributor to the advancement of modern medicine and treatment, enabling better understanding of the prevention, diagnosis, and treatment of a wide range of serious and life-threatening illnesses, including cancer, heart diseases, and stroke. The non-profit company is based in Stockport, UK, and has subsidiaries in the United Kingdom. The database includes blood samples, heart and brain scans, and genetic data that are accessible to approved researchers who are undertaking health-related research that is in the public interest. The CEO of the British company is Rory Collins.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

The Academy of Medical Sciences was founded in 1998 and provides biomedical and health research services. The non-profit company is based in London, UK.

Interplast is a group of individuals founded by Dr. Laub from Stanford University who are concerned with the maldistribution of medicine. Interplast is based in Sunnyvale, CA. The non-profit company provides direct care to people who do not have access to surgery and educate professionals. The group has inspired thousands of international humanitarian trips around the world by many surgeons who are motivated to change lives through plastic and reconstructive surgery.

StemPar Sciences, Inc. develops cancer drugs treatments. It provides cancer drugs that attack solid tumors by simultaneously disrupting their source of energy and their ability to repair chemotherapy/radiation induced DNA damage. The company was founded by Hoyoung Huh and Mircea Florin Mihaescu in 2012 and is headquartered in Mill Valley, CA.

CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA.

Resurge International operates surgical care facilities for poor children and adults.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Part of Peak Bio, Inc., Peak Bio Co. Ltd. is a South Korean clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and inflammation. Peak Bio's location is in Seongnam, South Korea. The company's lead product candidate, php-303, is a small molecule currently in phase II clinical study for the orphan disease alpha1 anti-trypsin deficiency. Peak Bio has successfully completed phase I trials, demonstrating dose-dependent pharmacokinetics and establishing a dose for upcoming clinical trials. The company's cancer platform includes novel payloads and antibody-drug-conjugates (ADC) to address unmet needs in cancer care. The company was founded in 2015, and the CEO is Ho Young Huh. Peak Bio Co. was acquired by Ignyte Acquisition Corp. on November 01, 2022 for $353.84 million.

Quintessa Investment acts as alternative investment manager. It is engaged in financial investment activities. The company was founded on January 13, 2011 and is headquartered in Seoul, South Korea.

Calibra Medical LLC develops and markets medical devices and technologies in the diabetes sector. Its products include finesse and insulin delivery devices. The company was founded by Daniel Hawkins and Clifton A. Alferness in 2004 and is headquartered in Wayne, PA.

pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea.

Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland.

Part of GSK Plc, GlaxoSmithKline AG is a company based in Munchenbuchsee, Switzerland.

Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA.

MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then.